BioCentury
ARTICLE | Clinical News

Amantadine: Completed Phase III enrollment

July 20, 2015 7:00 AM UTC

Adamas completed enrollment of about 120 patients in the double-blind, placebo-controlled, North American Phase III EASE LID trial evaluating 340 mg oral ADS-5102 once daily at bedtime for 26 weeks. ...